¼¼»ó ¾îµð¿¡µµ ¾ø´Â ´Ü ÇϳªÀÇ ´Ü¹éÁúÀ» ¸¸µé¾îµå¸®°Ú½À´Ï´Ù.

ÇÏ´Ü¿¡ »ó¼¼¿µ¿ªº° Ä«Å×°í¸®¸¦ ´­¸£½Ã¸é º¸´Ù ½±°Ô ¿øÇÏ´Â Á¦Ç°À» ãÀ»¼ö ÀÖ½À´Ï´Ù. We will be your companion with our high technology and sufficent Know -how. If press below, You could easily find out several kinds of related informations.


Ä«Å×°í¸® Cytokines & Growth Factor
CAT.NO LGP-11-012
PRODUCT Flt-3 Ligand, Rhesus (Macaque Fms-related Tyrosine Kinase 3 Ligand)
SIZE 10ug, 100ug, 250ug
PRICE KRW 285,000, 1,595,000, 2,622,000
Technical Parameters
Synonyms Flt3L, SL cytokine
Accession H9Z6V7
GeneID 719239
Source Escherichia coli.
Molecular Weight Approximately 18.0 kDa, a single non-glycosylated polypeptide chain containing 159 amino acids.
Quantity 10µg/100µg/250µg
AA Sequence TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVPSNLQD EELCGALWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQHP PSCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSSTLP PPRSPGALEA TALTAPQRP
Purity > 97 % by SDS-PAGE and HPLC analyses.
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human AML5 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 ¡¿ 106 IU/mg.
Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation Lyophilized from a 0.2 ¥ìm filtered solution in PBS, pH 7.4.
Endotoxin Less than 1 EU/¥ìg of rRhFlt-3L as determined by LAL method.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ¡Â -20 ¡ÆC. Further dilutions should be made in appropriate buffered solutions.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 ¡ÆC as supplied.
- 1 month, 2 to 8 ¡ÆC under sterile conditions after reconstitution.
- 3 months, -20 to -70 ¡ÆC under sterile conditions after reconstitution.
Usage This material is offered by Korea Lugen Sci for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
SDS-PAGE
Reference 1. Hacein-Bey S, Basile GD, Lemerle J, et al. 1998. Blood, 92: 4090-7.
2. Peters M, Solem F, Goldschmidt J, et al. 2001. Exp Hematol, 29: 146-55.
3. Beq S, Fontanet A, Theze J, et al. 2004. AIDS, 18: 2089-91.
4. Mahadevan D, Choi J, Cooke L, et al. 2009. Hum Genomics Proteomics, 2009: 453634.
5. Coates PT, Barratt-Boyes SM, Zhang L, et al. 2003. Blood, 102: 2513-21.
Background Flt-3 ligand (FL) is a recently identified hematopoietic cytokine whose activities are mediated by binding to the transmembrane glycoprotein Flt-3. Flt-3 was first discovered as a member of the class III subfamily of receptor tyrosine kinases (RTK) whose expression among hematopoietic cells was found to be restricted to highly enriched stem/progenitor cell populations. Additionally, class III RTKs include the receptors from SCF, M-CSF and PDGF. Not surprisingly, Flt-3 ligand is also structurally related to M-CSF and SCF. All three cytokines have been shown to exist both as type I transmembrane proteins and as soluble proteins. The predominant human FL isoform is a transmembrane protein that can undergo proteolytic cleavage to generate a soluble form of the protein. FL has been shown to synergize with a wide variety of hematopoietic cytokines to stimulate the growth and differentiation of early hematopoietic progenitors.

÷ºÎÆÄÀÏ

¸Þ´º´Ý±â

°ßÀû¹®ÀÇ

INQUIRY

¾Æ·¡ Ç׸ñ¿¡ ¸Â°Ô Á¤È®È÷ ÀÔ·ÂÇÏ¿© ÁֽʽÿÀ.